Help
RSS
API
Feed
Maltego
Contact
Domain > investors.werewolftx.com
×
More information on this domain is in
AlienVault OTX
Is this malicious?
Yes
No
DNS Resolutions
Date
IP Address
2022-02-08
104.96.183.113
(
ClassC
)
2025-01-17
104.93.21.114
(
ClassC
)
2025-08-02
23.216.147.208
(
ClassC
)
Port 443
HTTP/1.1 200 OKContent-Language: enContent-Type: text/html; charsetUTF-8ETag: 1754129381Expect-CT: max-age0, report-uri/report-expect-ct-violationFeature-Policy: accelerometer none;ambient-light-sensor none;autoplay self;camera none;encrypted-media none;fullscreen self;geolocation self;gyroscope none;magnetometer none;microphone none;midi none;payment none;picture-in-picture none;speaker self;sync-xhr self;usb none;vibrate none;vr noneFrom-Origin: sameLast-Modified: Sat, 02 Aug 2025 10:09:41 GMTReferrer-Policy: no-referrer-when-downgradeStrict-Transport-Security: max-age31536000X-Age: 1148X-Cache-Hits: 2X-Content-Type-Options: nosniffX-Drupal-Dynamic-Cache: UNCACHEABLE (poor cacheability)X-Frame-Options: SAMEORIGINX-Request-ID: v-ce4a311c-6f88-11f0-969a-2f79d51a37d1X-XSS-Protection: 1; modeblockX-EdgeConnect-MidMile-RTT: 28X-EdgeConnect-Origin-MEX-Latency: 63Cache-Control: public, max-age0, s-maxage2700Expires: Sat, 02 Aug 2025 10:28:51 GMTDate: Sat, 02 Aug 2025 10:28:51 GMTContent-Length: 26442Connection: keep-alive !DOCTYPE html>html langen dirltr prefixog: https://ogp.me/ns#> head> meta charsetutf-8 />meta namedescription contentThe Investor Relations website contains information about Werewolf Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. />link relcanonical hrefhttps://investors.werewolftx.com/investors/ />link relshortlink hrefhttps://investors.werewolftx.com/ />meta namereferrer contentno-referrer />meta propertyog:site_name contentWerewolf Therapeutics, Inc. />meta propertyog:type contentwebsite />meta propertyog:url contenthttps://investors.werewolftx.com/investors />meta propertyog:title contentInvestors | Werewolf Therapeutics, Inc. />meta propertyog:description contentThe Investor Relations website contains information about Werewolf Therapeutics, Inc.'s business for stockholders, potential investors, and financial analysts. />meta nameGenerator contentDrupal 10 (https://www.drupal.org) />meta nameMobileOptimized contentwidth />meta nameHandheldFriendly contenttrue />meta nameviewport contentwidthdevice-width, initial-scale1.0 />link relicon href/sites/g/files/knoqqb62791/files/favicon.png typeimage/png />link relalternate hreflangen hrefhttps://investors.werewolftx.com/ /> title>Investors | Werewolf Therapeutics, Inc./title> link relstylesheet mediaall href/sites/g/files/knoqqb62791/files/css/css_5QOHbD1tiaE6es-ebYw6Tmqf6KOiuRE2_BaNLRO6tkQ.css?delta0&languageen&themenir_pid4092&includeeJyNj8EOAjEIRH9oszXGi19DaEtWsi00FE327-26B_Vg4m2YDPAmqVHIdm9Y5sxYdJmEDSJ2CoXje9gFJ5X-bblqiWgvs6Kt5JDREWLRtAYULFt3MHSWZWwZpBua_xXv4BgL_chWQgGjpLWSDJ9VPm43XA6-XcwD20kc-iZpQIjQAdw4X07Xc9AHmXGmqY_vVMPe7gm7um4b />link relstylesheet mediaall href/sites/g/files/knoqqb62791/files/css/css_ajPJEcQd5UZPZ0Bnaqzefd26OM8RTQtl8HhJtOxpU70.css?delta1&languageen&themenir_pid4092&includeeJyNj8EOAjEIRH9oszXGi19DaEtWsi00FE327-26B_Vg4m2YDPAmqVHIdm9Y5sxYdJmEDSJ2CoXje9gFJ5X-bblqiWgvs6Kt5JDREWLRtAYULFt3MHSWZWwZpBua_xXv4BgL_chWQgGjpLWSDJ9VPm43XA6-XcwD20kc-iZpQIjQAdw4X07Xc9AHmXGmqY_vVMPe7gm7um4b />link relstylesheet mediaprint href/sites/g/files/knoqqb62791/files/css/css_P6I6tB4peKhbJxECEa1G8A7akr_KJH6S-dXMliCFgFk.css?delta2&languageen&themenir_pid4092&includeeJyNj8EOAjEIRH9oszXGi19DaEtWsi00FE327-26B_Vg4m2YDPAmqVHIdm9Y5sxYdJmEDSJ2CoXje9gFJ5X-bblqiWgvs6Kt5JDREWLRtAYULFt3MHSWZWwZpBua_xXv4BgL_chWQgGjpLWSDJ9VPm43XA6-XcwD20kc-iZpQIjQAdw4X07Xc9AHmXGmqY_vVMPe7gm7um4b />link relstylesheet mediaall href/sites/g/files/knoqqb62791/files/css/css_IlxO17oyF0oGJD2YCIG5ThP3xBKyKfVJwiRjGW3n9wM.css?delta3&languageen&themenir_pid4092&includeeJyNj8EOAjEIRH9oszXGi19DaEtWsi00FE327-26B_Vg4m2YDPAmqVHIdm9Y5sxYdJmEDSJ2CoXje9gFJ5X-bblqiWgvs6Kt5JDREWLRtAYULFt3MHSWZWwZpBua_xXv4BgL_chWQgGjpLWSDJ9VPm43XA6-XcwD20kc-iZpQIjQAdw4X07Xc9AHmXGmqY_vVMPe7gm7um4b /> script src/core/assets/vendor/modernizr/modernizr.min.js?v3.11.7>/script>script src/sites/g/files/knoqqb62791/files/js/js_clEO30NHnJLofG92s17FiCkatrgDVBGDBvss4EL21TA.js?scopeheader&delta1&languageen&themenir_pid4092&includeeJyVUNFqwzAM_KERl7KXPe8Lxj5AyJZotShWsJW1_fsmdqFbGYxisO_kO_msLAUwo15cUg35JxuQLDIoLjkdX_K_wrkYNVnEykEl3skG3EwjllZMI5O4FSD0dUXlGu6wSSYsI3sTQFRLY_izOiSbJsz0lKf6un8s5txti7pMayIMv2m7nfHQP7CBAb_wDEgESbFWQOXiPfAs9Lp72wf75lKEeuv2EqQjFg8PvKd43-CnX1TyoTlOHKs4Q7Z1tNwn_VAbbucVQ-uvRg>/script> script async src//www.googletagmanager.com/gtag/js?idUA-148438425-1>/script> script> window.dataLayer window.dataLayer || ; function gtag() { dataLayer.push( arguments ); } gtag( js, new Date() ); gtag( config, UA-148438425-1 ); /script> /head> body classbody-sidebars-none nir-node nir-node--type-nir-landing-page nir-node--5806 path-frontpage page-node-type-nir-landing-page> div idskip> a classvisually-hidden focusable skip-link href#main-menu> Skip to main navigation /a> /div> div classdialog-off-canvas-main-canvas data-off-canvas-main-canvas> header classheader inactive idheader> div classheader__wrapper> div classheader__logo__icon inview-animate--fade> a hrefhttps://werewolftx.com/>img src/sites/g/files/knoqqb62791/themes/site/nir_pid4092/dist/images/logo-icon.svg>/a> /div> div classheader__logo__icon header__logo__icon__alternative> a hrefhttps://werewolftx.com/>img src/sites/g/files/knoqqb62791/themes/site/nir_pid4092/dist/images/logo-icon-alternative.svg>/a> /div> div classheader__logo__text inview-animate--fade> a hrefhttps://werewolftx.com/>img src/sites/g/files/knoqqb62791/themes/site/nir_pid4092/dist/images/logo-text2.svg>/a> /div> div classheader__trigger inview-animate--fade idheader-trigger> span>/span> span>/span> span>/span> span>/span> span>/span> /div> div classheader__menu inactive idheader-menu> div classheader__menu__wrapper> ul idmenu-main classheader__menu__navigation header__menu__navigation--upper> li classheader__menu__item> a hrefhttps://werewolftx.com/our-science/ classheader__menu__item__link>Our Science/a> /li> li classheader__menu__item> a hrefhttps://werewolftx.com/our-pipeline/ classheader__menu__item__link>Our Pipeline/a> /li> li classheader__menu__item> a hrefhttps://werewolftx.com/clinical-trials/ classheader__menu__item__link>Clinical Trials/a> /li> li classheader__menu__item> a hrefhttps://werewolftx.com/our-team/ classheader__menu__item__link>Our Team/a> /li> li classheader__menu__item> a hrefhttps://werewolftx.com/join-our-team/ classheader__menu__item__link>Join Our Team/a> /li> li classheader__menu__item> a hrefhttps://werewolftx.com/contact/ classheader__menu__item__link>Contact/a> /li> li classheader__menu__item> a href/investors classactive header__menu__item__link is-active data-drupal-link-system-pathnode/5806 aria-currentpage>Investors/a> /li> /ul> ul idmenu-secondary classheader__menu__navigation header__menu__navigation--lower> li classheader__menu__item> a hrefhttps://werewolftx.com/terms-of-service/ classheader__menu__item__link>Terms of Service/a> /li> li classheader__menu__item> a hrefhttps://werewolftx.com/privacy-policy/ classheader__menu__item__link>Privacy Policy/a> /li> /ul> /div> /div> /div>/header>section classhero hero--big> div classhero__wrapper> div classhero__background hero__background--desktop stylebackground-image: url(/sites/g/files/knoqqb62791/themes/site/nir_pid4092/dist/images/hero-image.jpg);>/div> div classhero__background hero__background--mobile stylebackground-image: url(/sites/g/files/knoqqb62791/themes/site/nir_pid4092/dist/images/hero-image-mobile.jpg);>/div> h1 classhero__title hero__title--small>Investors/h1> /div>/section>section classnavigation> div classnavigation__wrapper> div classnavigation__items tabs__triggers--mobile> select classtabs_triggers_select> option value/investors>Overview/option> option value/news-and-events/press-releases>News & Resources/option> option value/stock-information/stock-quote-and-chart>Stock Information/option> option value/financial-information/sec-filings>SEC Filings/option> option value/corporate-governance/documents-and-charters>Corporate Governance/option> option value/investor-resources/investor-faqs>Contact & FAQs/option> /select> /div> nav classnavigation__items navigation__items--desktop> a href/investors classnavigation__item is-active data-drupal-link-system-pathnode/5806 aria-currentpage>Overview/a> a href/news-and-events/press-releases classnavigation__item data-drupal-link-system-pathnode/5816>News & Resources/a> a href/stock-information/stock-quote-and-chart classnavigation__item data-drupal-link-system-pathnode/5911>Stock Information/a> a href/financial-information/sec-filings classnavigation__item data-drupal-link-system-pathnode/6016>SEC Filings/a> a href/corporate-governance/documents-and-charters classnavigation__item data-drupal-link-system-pathnode/5836>Corporate Governance/a> a href/investor-resources/investor-faqs classnavigation__item data-drupal-link-system-pathnode/5941>Contact & FAQs/a> /nav> /div>/section> div idndq-content classndq-5806> div classregion region-content> div data-drupal-messages-fallback classhidden>/div>div idblock-nir-pid4092-content classblock--system-main-block block--system-main-block--5806 block--content--system-main-block block--content--system-main-block--5806 block--b281a5e0-eba7-4d83-9b29-72dea9cb31f2 block--b281a5e0-eba7-4d83-9b29-72dea9cb31f2--5806 block block-system block-system-main-block> article classnode node--type-nir_landing_page node--view-mode-full clearfix> h1> Investors /h1> div> div classpanel-display pond clearfix > div classcontainer-fluid> section classcontent> div classcontent__wrapper> div classblock-region-header>div classblock-content--nir-lp-block block-content--nir-lp-block--6031 block--block-content6055e09d-acfc-462d-a631-146f5f235b77 block--block-content6055e09d-acfc-462d-a631-146f5f235b77--5806 block--header--block-content--6055e09d-acfc-462d-a631-146f5f235b77 block--header--block-content--6055e09d-acfc-462d-a631-146f5f235b77--5806 block--e7158d3a-ac94-4712-a7eb-87b211130b26 block--e7158d3a-ac94-4712-a7eb-87b211130b26--5806 block block-block-content block-block-content6055e09d-acfc-462d-a631-146f5f235b77> div classfield field--name-field-nir-lp-block-node field--type-entity-reference field--label-hidden field__item> div classfield field--name-field-nir-lp-block-body field--type-text-long field--label-hidden field__item>h2 classcontent__title>Company Overview/h2>div classcontent__description>p>Werewolf Therapeutics, Inc. is an innovative clinical-stage biopharmaceutical company pioneering the development of therapeutics engineered to stimulate the body’s immune system for the treatment of cancer. We are leveraging our proprietary PREDATOR™ platform to design conditionally activated molecules that stimulate both adaptive and innate immunity with the goal of addressing the limitations of conventional proinflammatory immune therapies. Our INDUKINE™ molecules are intended to remain inactive in peripheral tissue yet activate selectively in the tumor microenvironment. Our most advanced product candidates, WTX-124 and WTX-330, are systemically delivered, conditionally activated Interleukin-2 (IL-2), and Interleukin-12 (IL-12) INDUKINE molecules for the treatment of solid tumors. WTX-124 is in development as a monotherapy and in combination with KEYTRUDA® (pembrolizumab) in multiple solid tumor types. WTX-330 is in development as a single agent in refractory and/or immunotherapy unresponsive or resistant advanced or metastatic solid tumors and non-Hodgkin lymphoma./p>/div>/div> /div> /div> div > a href/investor-resources/email-alerts classcontact__button title data-drupal-link-system-pathnode/5946>Sign up for email alerts/a> /div> /div> /div> /section> section classstock> div classstock__wrapper> div classstock__container> div classblock-region-column1>div data-storage-idnode:5806:full:15756 data-uuidef6147b4-5c48-4bb5-a249-efadc198f426 classblock--market-data-block__stock-quote block--market-data-block__stock-quote--5806 block--column1--market-data-block__stock-quote block--column1--market-data-block__stock-quote--5806 block--ef6147b4-5c48-4bb5-a249-efadc198f426 block--ef6147b4-5c48-4bb5-a249-efadc198f426--5806 block block-nir-market-data-block block-market-data-block__stock-quote> h2 classh3 stock__title>Stock Information/h2> div classstock-quote stock-quote__short> div classquote-wrapper> div classstock__details> div classstock__details__header> span classstock__details__header__item>/span> span classstock__details__header__item>Aug 2, 2025/span> /div> div classstock__details__content> span classstock__details__content__price>/span> span classstock__details__content__profit>/span> /div> /div> /div>/div> /div>div classblock--attribution-block__stock-info-attribution__thomson-reuters block--attribution-block__stock-info-attribution__thomson-reuters--5806 block--column1--attribution-block__stock-info-attribution__thomson-reuters block--column1--attribution-block__stock-info-attribution__thomson-reuters--5806 block--2f58128a-1a49-4441-8f00-f948675b17d4 block--2f58128a-1a49-4441-8f00-f948675b17d4--5806 block block-nir-attribution-block block-attribution-block__stock-info-attribution__thomson-reuters> p classattribution-legend> Minimum 15 minutes delayed. Source: LSEG/p> /div> div > a href/stock-information/stock-quote-and-chart classstock__details__button title data-drupal-link-system-pathnode/5911>More Information/a> /div> /div> div classstock__chart mt-5> div classblock-region-column2>div classblock--nir-stock-chart block--nir-stock-chart--5806 block--column2--nir-stock-chart block--column2--nir-stock-chart--5806 block--b80fadcc-5376-4418-86bb-967708b4e3ba block--b80fadcc-5376-4418-86bb-967708b4e3ba--5806 block block-nir-stock-chart> img srchttps://api.nasdaqomx.wallst.com/api/chart?displaymountain&symbolHOWL.O-HOWL&scalelinear&duration1dy&frequency15min&gridLineh&bgColore7e7e7&lineColorc4a800&fillcolore5d88d|ffffff&width740&height280&bdr2&volume0 width740 height280 >/img> /div>/div> /div> /div> /div> /section> section classlisting> div classlisting__wrapper> div classlisting__column> div classblock-region-column3>div classblock--events block--nir-events__widget block--nir-events__widget--5806 block--column3--nir-events__widget block--column3--nir-events__widget--5806 block--9fdc82d4-4b55-42df-a5a0-922505cf6c6e block--9fdc82d4-4b55-42df-a5a0-922505cf6c6e--5806 block block-nir-events block-nir-events__widget> div classnir-widget> h2 classh3 listing__title> Events & Presentations /h2> div classnir-widget--content> div classnir-widget--list> div classlisting__items> div classlisting__item> time classlisting__item__date> div classndq-date> June 5, 2025 span classndq-hide>at 4:20 PM EDT/span> /div> /time> div classnir-widget--field nir-widgets--event--title listing__item__name> div classfield-nir-event-title> div classfield__item>a href/events/event-details/jefferies-global-healthcare-conference-0 hreflangen>Jefferies Global Healthcare Conference/a>/div> /div> /div> div classtabs__content__buttons mt-4> /div> /div>div classlisting__item> time classlisting__item__date> div classndq-date> May 14, 2025 span classndq-hide>at 3:15 PM PDT/span> /div> /time> div classnir-widget--field nir-widgets--event--title listing__item__name> div classfield-nir-event-title> div classfield__item>a href/events/event-details/bank-america-securities-2025-health-care-conference hreflangen>Bank of America Securities 2025 Health Care Conference/a>/div> /div> /div> div classtabs__content__buttons mt-4> /div> /div> /div> /div> div classnir-widget--pager> /div> div classnir-widget--total-results> /div> /div>/div> /div> div > a href/news-and-events/events classlisting__button title data-drupal-link-system-pathnode/5821>All Events/a> /div> /div> /div> div classlisting__column> div classblock-region-secondarycolumn1>div classblock--news block--nir-news__widget block--nir-news__widget--5806 block--secondarycolumn1--nir-news__widget block--secondarycolumn1--nir-news__widget--5806 block--3af540cd-fdfd-4b45-b154-d5c0bb32e60c block--3af540cd-fdfd-4b45-b154-d5c0bb32e60c--5806 block block-nir-news block-nir-news__widget> div classnir-widget> h2 classh3 listing__title> Latest Press Releases /h2> div classnir-widget--content> div classnir-widget--list> div classlisting__items-> div classlisting__item> time classlisting__item__date> July 9, 2025 /time> div classnir-widget--field nir-widget--news--headline listing__item__name> a href/news-releases/news-release-details/werewolf-therapeutics-participate-kidneycan-7th-annual-kidney hreflangen>Werewolf Therapeutics to Participate in the KidneyCAN 7th Annual Kidney Cancer Research Summit/a> /div> /div>div classlisting__item> time classlisting__item__date> June 12, 2025 /time> div classnir-widget--field nir-widget--news--headline listing__item__name> a href/news-releases/news-release-details/werewolf-therapeutics-participate-bio-international-convention hreflangen>Werewolf Therapeutics to Participate in the BIO International Convention/a> /div> /div> /div> /div> div classnir-widget--pager> /div> div classnir-widget--total-results> /div> /div>/div> /div> div > a href/news-and-events/press-releases classlisting__button title data-drupal-link-system-pathnode/5816>All Press Releases/a> /div> /div> /div> /div> /section> /div>/div>!-- /.radix-pond --> /div>/article> /div>div idblock-nir-pid4092-websitenoticeblock classblock--website-notice-block block--website-notice-block--5806 block--content--website-notice-block block--content--website-notice-block--5806 block--7632596d-0db0-4df1-9a88-bf4215c52390 block--7632596d-0db0-4df1-9a88-bf4215c52390--5806 block block-nir-website-notices block-website-notice-block> /div> /div> /div> section classcontact> div classcontact__wrapper> div classcontact__background stylebackground-image: url(/sites/g/files/knoqqb62791/themes/site/nir_pid4092/dist/images/contact-image.jpg);>/div> div classregion region-contact> div idblock-nir-pid4092-gbircontact classblock-content--nir-global-block block-content--nir-global-block--6106 block--block-contenta9d8db78-a2bc-41d8-add0-237685a02822 block--block-contenta9d8db78-a2bc-41d8-add0-237685a02822--5806 block--contact--block-content--a9d8db78-a2bc-41d8-add0-237685a02822 block--contact--block-content--a9d8db78-a2bc-41d8-add0-237685a02822--5806 block--3217e040-2f24-4b72-a66a-111b1653af16 block--3217e040-2f24-4b72-a66a-111b1653af16--5806 block block-block-content block-block-contenta9d8db78-a2bc-41d8-add0-237685a02822> div classfield field--name-field-nir-global-block-node field--type-entity-reference field--label-hidden field__item> div classfield field--name-field-nir-global-block-body field--type-text-long field--label-hidden field__item>h2 classh3 contact__title>Investor Contact/h2>div classcontact__item>a classcontact__item__link hrefmailto:IR@werewolftx.com>IR@werewolftx.com/a>/div> br> /div> /div> /div> div > a href/investor-resources/email-alerts classcontact__button title data-drupal-link-system-pathnode/5946>Sign up for email alerts/a> /div> /div> /div> /section>footer classfooter idfooter> div classfooter__wrapper> div classfooter__copyright inview-animate--move-right> span classfooter__copyright__year>© 2025 /span> span classfooter__copyright__text>Werewolf Therapeutics, Inc.. All rights reserved./span> /div> div classfooter__menu inview-animate--move-left> ul classfooter__menu__navigation> li classfooter__menu__item> a hrefhttps://werewolftx.com/terms-of-service/>Terms of Service/a> /li> li classfooter__menu__item> a hrefhttps://werewolftx.com/privacy-policy/>Privacy Policy/a> /li> /ul> /div> /div>/footer> /div> script typetext/javascript>var s_CCSWebHostingAccount trcgwerewolftx;/script> script typeapplication/json data-drupal-selectordrupal-settings-json>{path:{baseUrl:\/,pathPrefix:,currentPath:node\/5806,currentPathIsAdmin:false,isFront:true,currentLanguage:en},pluralDelimiter:\u0003,suppressDeprecationErrors:true,ajaxPageState:{libraries:eJyVUu1uwyAMfKEoTNP-7PeeYNoDIANWywJ2hJ21efsRqNSl6r4UifiOs3XYplgsEKRVoxdDX9EIgR3aBAv540C_CufCockcCJoU3RVsQfRMsqeUOTkojfQThqhcbACtn0so5ho2SYYyoTaBdYn9ZJoFUVtAIx1q4VrnCEX_JBfban-jzQhkC3rOGanykenH2nfZcUsHCv_KEa3n68J6sbYkjbk2B8wettsZDr2XWzDCO5wthGB9AhELCYvKHV0dhSKplZV87RoR9iHMMTw9PD8a_sBSYugGmp_-dnODu9eXLXzTNdWmtowTOomKlriuB_ZtueHGy38oEOK5LtnKi4rZoUHqsDCbbV8-AQp5DV8,theme:nir_pid4092,theme_token:null},ajaxTrustedUrl:,nir_admin_use_chosen:true,nir_admin_use_select2:false,user:{uid:0,permissionsHash:ba9222eaa185628ff83c8541e14cf06303ab95cf82e3cedc08966dfd27fa3cb9}}/script>script src/sites/g/files/knoqqb62791/themes/site/nir_pid4092/dist/js/main.js?szfh1o>/script>script srchttps://code.jquery.com/jquery-3.5.1.min.js>/script>script src/sites/g/files/knoqqb62791/files/js/js_GKN45RE7diS2L89-BvjeWdc_3JpHOhEzQBTeMhAbq7Q.js?scopefooter&delta2&languageen&themenir_pid4092&includeeJyVUNFqwzAM_KERl7KXPe8Lxj5AyJZotShWsJW1_fsmdqFbGYxisO_kO_msLAUwo15cUg35JxuQLDIoLjkdX_K_wrkYNVnEykEl3skG3EwjllZMI5O4FSD0dUXlGu6wSSYsI3sTQFRLY_izOiSbJsz0lKf6un8s5txti7pMayIMv2m7nfHQP7CBAb_wDEgESbFWQOXiPfAs9Lp72wf75lKEeuv2EqQjFg8PvKd43-CnX1TyoTlOHKs4Q7Z1tNwn_VAbbucVQ-uvRg>/script>script srchttps://assets.adobedtm.com/898335afd880/c52ee8aa1e90/launch-5ef258dce664.min.js crossoriginanonymous async integritysha384-9QSqHMB+yiy/V4i+d2Au+ydEWbBz4E9DqsE+oYKOnL+kj4XAZGYZxabd0P3OGHkf>/script>script src/sites/g/files/knoqqb62791/files/js/js_e_oZkKTgUxZGyD3AjLCtri9NZIlGrVGrtlGLR3WXesE.js?scopefooter&delta4&languageen&themenir_pid4092&includeeJyVUNFqwzAM_KERl7KXPe8Lxj5AyJZotShWsJW1_fsmdqFbGYxisO_kO_msLAUwo15cUg35JxuQLDIoLjkdX_K_wrkYNVnEykEl3skG3EwjllZMI5O4FSD0dUXlGu6wSSYsI3sTQFRLY_izOiSbJsz0lKf6un8s5txti7pMayIMv2m7nfHQP7CBAb_wDEgESbFWQOXiPfAs9Lp72wf75lKEeuv2EqQjFg8PvKd43-CnX1TyoTlOHKs4Q7Z1tNwn_VAbbucVQ-uvRg>/script>script src/core/assets/vendor/ckeditor5/ckeditor5-dll/ckeditor5-dll.js?v44.0.0>/script>script src/profiles/nasdaqir/modules/custom/nir_ckeditor_datatables/js/build/datatables.js?v1.10.9>/script>script src/sites/g/files/knoqqb62791/files/js/js_z7IPjhARvdRHhMlZAmfVtaNiDFA7K4JGrP8WjlQX0z4.js?scopefooter&delta7&languageen&themenir_pid4092&includeeJyVUNFqwzAM_KERl7KXPe8Lxj5AyJZotShWsJW1_fsmdqFbGYxisO_kO_msLAUwo15cUg35JxuQLDIoLjkdX_K_wrkYNVnEykEl3skG3EwjllZMI5O4FSD0dUXlGu6wSSYsI3sTQFRLY_izOiSbJsz0lKf6un8s5txti7pMayIMv2m7nfHQP7CBAb_wDEgESbFWQOXiPfAs9Lp72wf75lKEeuv2EqQjFg8PvKd43-CnX1TyoTlOHKs4Q7Z1tNwn_VAbbucVQ-uvRg>/script> /body>/html>
View on OTX
|
View on ThreatMiner
Please enable JavaScript to view the
comments powered by Disqus.
Data with thanks to
AlienVault OTX
,
VirusTotal
,
Malwr
and
others
. [
Sitemap
]